Journal PubWeight™ 33085.30‹?›

Top papers

Rank Title Year PubWeight™‹?›
1 Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. 1984 119.59
2 The Clinical Dementia Rating (CDR): current version and scoring rules. 1993 47.72
3 Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). 1983 40.64
4 Parkinsonism: onset, progression and mortality. 1967 36.06
5 Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. 1998 26.77
6 The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. 1991 23.01
7 Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. 2005 21.67
8 The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. 1994 21.65
9 Revised diagnostic criteria for neuromyelitis optica. 2006 17.57
10 Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. 1993 16.92
11 The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer's disease. 1989 16.83
12 Updated research nosology for HIV-associated neurocognitive disorders. 2007 16.18
13 Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease. 1993 14.54
14 Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. 1996 12.33
15 HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. 2010 12.32
16 [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. 2006 12.10
17 Classification of primary progressive aphasia and its variants. 2011 11.82
18 A brief cognitive test battery to differentiate Alzheimer's disease and frontotemporal dementia. 2000 10.75
19 Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. 1996 10.26
20 Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment. 1999 9.86
21 The minimally conscious state: definition and diagnostic criteria. 2002 9.67
22 Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. 1992 9.30
23 Mixed brain pathologies account for most dementia cases in community-dwelling older persons. 2007 9.27
24 Proposed diagnostic criteria for neurocysticercosis. 2001 9.15
25 Neuropathology of older persons without cognitive impairment from two community-based studies. 2006 8.97
26 The FAB: a Frontal Assessment Battery at bedside. 2000 8.93
27 Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. 1996 8.82
28 Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. 1995 8.63
29 Medial temporal atrophy on MRI in normal aging and very mild Alzheimer's disease. 1997 8.50
30 Revised diagnostic criteria for the pseudotumor cerebri syndrome in adults and children. 2013 8.25
31 Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group. 1993 8.21
32 Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. 2008 8.10
33 Neuropathic pain: redefinition and a grading system for clinical and research purposes. 2007 8.08
34 The clinical course of neuromyelitis optica (Devic's syndrome). 1999 8.03
35 Phases of A beta-deposition in the human brain and its relevance for the development of AD. 2002 7.73
36 Imaging beta-amyloid burden in aging and dementia. 2007 7.70
37 Practice parameter: early detection of dementia: mild cognitive impairment (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. 2001 7.68
38 Diabetes mellitus and the risk of dementia: The Rotterdam Study. 1999 7.55
39 Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. 2001 7.51
40 Evaluating storage, retention, and retrieval in disordered memory and learning. 1974 7.34
41 A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group. 1998 7.27
42 Second consensus statement on the diagnosis of multiple system atrophy. 2008 7.27
43 Assessment: neuropsychological testing of adults. Considerations for neurologists. Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. 1996 7.23
44 Brain death worldwide: accepted fact but no global consensus in diagnostic criteria. 2002 7.20
45 Evidence-based guideline update: Plasmapheresis in neurologic disorders: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. 2011 7.09
46 Alzheimer's Disease Neuroimaging Initiative (ADNI): clinical characterization. 2009 7.04
47 Sustained excitability elevations induced by transcranial DC motor cortex stimulation in humans. 2001 7.03
48 Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. 2006 6.86
49 Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. 1988 6.79
50 How common are the "common" neurologic disorders? 2007 6.77
Next 50